TWI719277B - 人類rpe細胞之醫藥組合物及其用途 - Google Patents

人類rpe細胞之醫藥組合物及其用途 Download PDF

Info

Publication number
TWI719277B
TWI719277B TW107102515A TW107102515A TWI719277B TW I719277 B TWI719277 B TW I719277B TW 107102515 A TW107102515 A TW 107102515A TW 107102515 A TW107102515 A TW 107102515A TW I719277 B TWI719277 B TW I719277B
Authority
TW
Taiwan
Prior art keywords
cells
rpe
cell
rpe cells
human
Prior art date
Application number
TW107102515A
Other languages
English (en)
Chinese (zh)
Other versions
TW201828960A (zh
Inventor
蓋羅吉
克林曼斯卡亞艾瑞那
蘭薩羅伯特
Original Assignee
美商安斯泰來再生醫藥協會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47470610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI719277(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商安斯泰來再生醫藥協會 filed Critical 美商安斯泰來再生醫藥協會
Publication of TW201828960A publication Critical patent/TW201828960A/zh
Application granted granted Critical
Publication of TWI719277B publication Critical patent/TWI719277B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mechanical Engineering (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
TW107102515A 2011-11-14 2012-11-14 人類rpe細胞之醫藥組合物及其用途 TWI719277B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161559521P 2011-11-14 2011-11-14
US61/559,521 2011-11-14
US201261589741P 2012-01-23 2012-01-23
US61/589,741 2012-01-23
US201261724047P 2012-11-08 2012-11-08
US61/724,047 2012-11-08

Publications (2)

Publication Number Publication Date
TW201828960A TW201828960A (zh) 2018-08-16
TWI719277B true TWI719277B (zh) 2021-02-21

Family

ID=47470610

Family Applications (5)

Application Number Title Priority Date Filing Date
TW107102515A TWI719277B (zh) 2011-11-14 2012-11-14 人類rpe細胞之醫藥組合物及其用途
TW113103167A TW202434266A (zh) 2011-11-14 2012-11-14 人類rpe細胞之醫藥組合物及其用途
TW111133463A TWI842079B (zh) 2011-11-14 2012-11-14 人類ｒｐｅ細胞之醫藥組合物及其用途
TW101142511A TWI655286B (zh) 2011-11-14 2012-11-14 人類ｒｐｅ細胞之醫藥組合物及其用途
TW109136186A TWI785403B (zh) 2011-11-14 2012-11-14 人類rpe細胞之醫藥組合物及其用途

Family Applications After (4)

Application Number Title Priority Date Filing Date
TW113103167A TW202434266A (zh) 2011-11-14 2012-11-14 人類rpe細胞之醫藥組合物及其用途
TW111133463A TWI842079B (zh) 2011-11-14 2012-11-14 人類ｒｐｅ細胞之醫藥組合物及其用途
TW101142511A TWI655286B (zh) 2011-11-14 2012-11-14 人類ｒｐｅ細胞之醫藥組合物及其用途
TW109136186A TWI785403B (zh) 2011-11-14 2012-11-14 人類rpe細胞之醫藥組合物及其用途

Country Status (23)

Country Link
US (4) US20130195806A1 (enExample)
EP (2) EP3563860A1 (enExample)
JP (7) JP6506023B2 (enExample)
KR (1) KR102054904B1 (enExample)
CN (2) CN104080464A (enExample)
AU (5) AU2012340020A1 (enExample)
CA (2) CA2855941A1 (enExample)
CY (1) CY1121819T1 (enExample)
DK (1) DK2780022T4 (enExample)
ES (1) ES2734453T3 (enExample)
FI (1) FI2780022T4 (enExample)
GB (1) GB2496969A (enExample)
HK (1) HK1202456A1 (enExample)
HR (1) HRP20191110T1 (enExample)
HU (1) HUE044778T2 (enExample)
IL (5) IL320536A (enExample)
LT (1) LT2780022T (enExample)
PL (1) PL2780022T3 (enExample)
PT (1) PT2780022T (enExample)
RS (1) RS59050B1 (enExample)
SI (1) SI2780022T1 (enExample)
TW (5) TWI719277B (enExample)
WO (1) WO2013074681A1 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2929782A1 (en) * 2004-01-23 2015-10-14 Ocata Therapeutics, Inc. Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
DK2209888T3 (da) 2007-10-12 2020-01-20 Astellas Inst For Regenerative Medicine Forbedrede fremgangsmåder til fremstilling af rpe-celler og sammensætninger af rpe-celler
WO2011063005A2 (en) 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
US10852069B2 (en) 2010-05-04 2020-12-01 Fractal Heatsink Technologies, LLC System and method for maintaining efficiency of a fractal heat sink
WO2012012803A2 (en) 2010-07-23 2012-01-26 Advanced Cell Technology, Inc. Methods for detection of rare subpopulations of cells and highly purified compositions of cells
CA2849354C (en) 2011-09-26 2021-11-09 Preanalytix Gmbh Stabilisation and isolation of extracellular nucleic acids
US11021733B2 (en) 2011-09-26 2021-06-01 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
ES2687126T3 (es) 2011-09-26 2018-10-23 Qiagen Gmbh Estabilización y aislamiento de ácidos nucleicos extracelulares
WO2013074681A1 (en) * 2011-11-14 2013-05-23 Advanced Cell Technology, Inc. Pharmaceutical preparations of human rpe cells and uses thereof
AU2013322643C1 (en) 2012-09-25 2018-11-08 Qiagen Gmbh Stabilisation of biological samples
US20150368713A1 (en) 2013-02-01 2015-12-24 THE UNITED STATES OF AMERICAN, as represented by the Secretary, Department of Health and Human Serv METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs)
EP2976424B1 (en) 2013-03-18 2018-10-03 Qiagen GmbH Stabilisation of biological samples
WO2014146782A1 (en) 2013-03-18 2014-09-25 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
MX2016006915A (es) 2013-11-27 2017-01-23 Kyoto Prefectural Public Univ Corp Aplicacion de laminina a cultivo de celulas endoteliales de la cornea.
CN105814194A (zh) 2013-12-11 2016-07-27 辉瑞有限公司 产生视网膜色素上皮细胞的方法
EP2898896A1 (en) * 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
CN106102766A (zh) * 2014-01-22 2016-11-09 皮埃尔与玛丽·居里大学 - 巴黎第六大学 用于治疗视网膜炎症的试剂
EP3119197A1 (en) * 2014-03-18 2017-01-25 Qiagen GmbH Stabilization and isolation of extracellular nucleic acids
WO2015175504A1 (en) * 2014-05-12 2015-11-19 The Johns Hopkins University Differentiation of human pluripotent stem cells into retinal pigment epithelium using hif1 inhibitors
WO2015175783A1 (en) * 2014-05-15 2015-11-19 International Stem Cell Corporation Chemical differentiation of pluripotentstem cells into retinal epithelial cells
US10597633B2 (en) 2014-05-16 2020-03-24 Koninklijke Nederlandse Akademie Van Wetenschappen Culture method for organoids
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US20160095307A1 (en) 2014-10-07 2016-04-07 NuTech Medical, Inc. Method and composition for hypothermic storage of placental tissue
KR102210104B1 (ko) 2014-10-17 2021-02-01 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
EP3213762B1 (en) * 2014-10-31 2023-11-29 Kyoto Prefectural Public University Corporation Novel treatment of cornea using laminin
JP6770435B2 (ja) * 2014-10-31 2020-10-14 京都府公立大学法人 ラミニンによる網膜および神経の新規治療
KR102728629B1 (ko) * 2014-12-18 2024-11-12 쏘흐본느 유니베흐시테 망막 변성의 치료를 위한 otx2를 과발현하는 형질전환 rpe 세포
KR20170115514A (ko) * 2014-12-30 2017-10-17 셀 큐어 뉴로사이언시스 리미티드 Rpe 세포 집단 및 이를 생성하는 방법
MX2017008818A (es) 2014-12-30 2018-03-14 Cell Cure Neurosciences Ltd Metodos para tratar enfermedades de la retina.
EP3916085A1 (en) 2014-12-30 2021-12-01 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
CN118995872A (zh) * 2015-03-23 2024-11-22 安斯泰来再生医药协会 改进的人视网膜色素（rpe）细胞和感光祖细胞的效能测定
CN105013010B (zh) * 2015-07-07 2018-01-12 中山大学中山眼科中心 一种辅助iPS‑RPE移植的层粘连蛋白膜
WO2017021973A1 (en) 2015-08-05 2017-02-09 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
KR102651291B1 (ko) 2015-08-18 2024-03-26 아스텔라스 인스티튜트 포 리제너러티브 메디슨 임상 제제
EP4001402A1 (en) * 2015-09-08 2022-05-25 FUJIFILM Cellular Dynamics, Inc. Macs-based purification of stem cell-derived retinal pigment epithelium
EP3377645B1 (en) 2015-11-20 2023-10-04 Qiagen GmbH Method of preparing sterilized compositions for stabilization of extracellular nucleic acids
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
CN106420809B (zh) * 2016-08-31 2017-08-08 浙江济民制药股份有限公司 一种眼科手术灌注液
EP3555266B1 (en) * 2016-12-13 2023-11-15 The United States of America, as Represented by The Secretary, Department of Health and Human Services Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US11076984B2 (en) * 2017-03-13 2021-08-03 Gyroscope Therapeutics Limited Method of performing subretinal drainage and agent delivery
KR20200031559A (ko) * 2017-03-16 2020-03-24 리니지 셀 테라퓨틱스, 인크. 망막 질환 요법의 치료 효과를 측정하는 방법
CA3061900A1 (en) * 2017-05-01 2018-11-08 The Board Of Supervisors Of Louisiana State University And Agriculturaand Mechanical College Compositions and methods for treating ocular pathologies
KR102725720B1 (ko) * 2017-12-29 2024-11-06 셀 큐어 뉴로사이언시스 리미티드 망막 색소 상피 세포 조성물
CN112351755A (zh) 2018-02-22 2021-02-09 伊万提斯公司 眼部植入物和输送系统
CN112203679A (zh) * 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CN113226387B (zh) * 2018-11-19 2024-02-23 美国政府(由卫生和人类服务部的部长所代表) 可生物降解的组织置换植入物及其用途
GB201819224D0 (en) 2018-11-26 2019-01-09 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatocyte expansion methods
WO2020117898A1 (en) * 2018-12-05 2020-06-11 Abeona Therapeutics Inc. Recombinant adeno-associated viral vector for gene delivery
EP3976765A1 (en) * 2019-05-28 2022-04-06 F. Hoffmann-La Roche AG Method to generate monocytic progenitor cells
KR102198942B1 (ko) * 2019-07-02 2021-01-05 의료법인 성광의료재단 Pedf를 발현하거나 모세포에 비하여 pedf를 과발현하도록 유전적으로 조작된 중간엽 줄기세포
EP4013297A4 (en) 2019-08-16 2023-12-13 Poltorak Technologies, LLC DEVICE AND METHOD FOR MEDICAL DIAGNOSTICS
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
BR112022006644A2 (pt) 2019-10-30 2022-07-12 Astellas Inst For Regenerative Medicine Métodos para a produção de células epiteliais de pigmento da retina
US20230038379A1 (en) * 2019-11-22 2023-02-09 Sigilon Therapeutics, Inc. Monoclonal cell lines expressing an exogenous substance and uses thereof
CN115135148A (zh) 2020-01-21 2022-09-30 武田药品工业株式会社 冷冻保存细胞的组合物和方法
CA3167195A1 (en) * 2020-02-07 2021-08-12 The Trustees Of Columbia University In The City Of New York Reprogramming the metabolome to delay onset or treat neurodegeneration
JPWO2022009969A1 (enExample) * 2020-07-10 2022-01-13
CN112544612A (zh) * 2020-12-18 2021-03-26 江苏艾尔康生物医药科技有限公司 冻存液及其在rpe细胞冻存中的应用
CN112834411B (zh) * 2021-01-07 2022-05-27 上海交通大学 应用于质谱流式技术的金属纳米探针及制备方法和应用
CN112926116B (zh) * 2021-03-01 2023-02-17 哈尔滨工业大学 一种基于虚拟现实的体育馆火灾疏散行为数据收集系统及其收集方法
CN114246938A (zh) * 2022-01-25 2022-03-29 中山大学中山眼科中心 Il-4在制备用于治疗视网膜变性疾病药物中的应用
WO2023149420A1 (ja) * 2022-02-01 2023-08-10 株式会社坪田ラボ 近視を予防または治療するための方法および組成物
CN114561356B (zh) * 2022-03-09 2022-09-13 北京呈诺医学科技有限公司 影响细胞因子分泌的方法及应用
CA3254454A1 (en) * 2022-03-16 2025-03-04 Racthera Co., Ltd. METHOD OF TRANSPLANTATION
WO2024218311A1 (fr) * 2023-04-21 2024-10-24 Pulsesight Therapeutics Compositions à base de décorine pour la réparation et la régéneration de l'épithélium pigmentaire de la rétine
CN121079095A (zh) * 2023-05-05 2025-12-05 加利福尼亚大学董事会 视网膜色素上皮细胞疗法
CN117625536B (zh) * 2024-01-26 2024-04-30 中国人民解放军总医院第三医学中心 一种人视网膜色素上皮细胞的纯化、培养方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101563449A (zh) * 2006-09-22 2009-10-21 理化学研究所 干细胞培养基及干细胞培养方法
WO2011063005A2 (en) * 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138205A (en) 1975-12-15 1979-02-06 Hydro Pulse Corporation Movable stator walls permitting access to tubing in peristaltic pump
US5610753A (en) 1991-12-12 1997-03-11 Eastman Kodak Company Optical design of laser scanner to reduce thermal sensitivity
GB9608145D0 (en) * 1996-04-19 1996-06-26 British Tech Group Wound healing
US20040086494A1 (en) * 1996-10-07 2004-05-06 John Constance Mary Immune privileged cells for delivery of proteins and peptides
US5998423A (en) 1996-10-08 1999-12-07 Therasys, Inc. Methods for modulating melanin production
US6440933B1 (en) 1997-09-10 2002-08-27 University Of Florida Compounds and method for the prevention and treatment of diabetic retinopathy
CA2317115A1 (en) * 1998-01-02 1999-07-15 Titan Pharmaceuticals, Inc. Use of pigmented retinal epithelial cells for creation of an immune privilege site
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6576422B1 (en) * 2000-10-17 2003-06-10 Rohm And Haas Company Method for identifying products employing gene expression
AU3649502A (en) 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US20020192738A1 (en) * 2001-04-27 2002-12-19 Janice Brissette Tyrosinase assay
JP2004538005A (ja) * 2001-08-08 2004-12-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア シアル酸に結合するタンパク質を有するウイルスベクターの精製法
AU2002360424A1 (en) 2001-11-26 2003-06-10 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
US20030217374A1 (en) 2002-01-15 2003-11-20 Advanced Cell Technology Cloning B and T lymphocytes
US20040091936A1 (en) 2002-05-24 2004-05-13 Michael West Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank
US7803750B2 (en) 2002-07-29 2010-09-28 Duke University Method of modulating melanin production
US7794704B2 (en) * 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
EP2929782A1 (en) * 2004-01-23 2015-10-14 Ocata Therapeutics, Inc. Improved modalities for the treatment of degenerative diseases of the retina
US7309487B2 (en) * 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
US7838727B2 (en) 2004-11-04 2010-11-23 Advanced Cell Technology, Inc. Derivation of embryonic stem cells
DK2209888T3 (da) * 2007-10-12 2020-01-20 Astellas Inst For Regenerative Medicine Forbedrede fremgangsmåder til fremstilling af rpe-celler og sammensætninger af rpe-celler
GB0806746D0 (en) 2008-04-14 2008-05-14 Ucl Business Plc Membrane
US9173862B2 (en) * 2008-04-18 2015-11-03 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona Methods and compositions for treating and identifying compounds to treat age-related macular degeneration
WO2012012803A2 (en) * 2010-07-23 2012-01-26 Advanced Cell Technology, Inc. Methods for detection of rare subpopulations of cells and highly purified compositions of cells
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
WO2012135621A2 (en) 2011-03-30 2012-10-04 Cellular Dynamics International. Inc Priming of pluripotent stem cells for neural differentiation
JP6200883B2 (ja) * 2011-04-29 2017-09-20 ユニヴァーシティー オブ サザン カリフォルニア ポリマー基質上の幹細胞由来網膜色素上皮細胞の低温保存方法
WO2013074681A1 (en) 2011-11-14 2013-05-23 Advanced Cell Technology, Inc. Pharmaceutical preparations of human rpe cells and uses thereof
PL3189135T3 (pl) * 2014-09-05 2021-12-20 Astellas Institute For Regenerative Medicine Komórki zwojowe siatkówki i ich progenitory

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101563449A (zh) * 2006-09-22 2009-10-21 理化学研究所 干细胞培养基及干细胞培养方法
WO2011063005A2 (en) * 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells

Also Published As

Publication number Publication date
AU2012340020A1 (en) 2014-07-03
JP2019189614A (ja) 2019-10-31
KR20140096368A (ko) 2014-08-05
JP2022130370A (ja) 2022-09-06
AU2021204719B2 (en) 2024-11-21
CA2855941A1 (en) 2013-05-23
EP2780022A4 (en) 2015-08-05
CN104080464A (zh) 2014-10-01
JP2018048144A (ja) 2018-03-29
US20150366915A1 (en) 2015-12-24
TW201828960A (zh) 2018-08-16
AU2019201201A1 (en) 2019-03-14
US20200405767A1 (en) 2020-12-31
KR102054904B1 (ko) 2019-12-11
WO2013074681A9 (en) 2013-11-28
LT2780022T (lt) 2019-07-10
RS59050B1 (sr) 2019-08-30
TW202434266A (zh) 2024-09-01
US20250134932A1 (en) 2025-05-01
JP6899865B2 (ja) 2021-07-07
JP6563996B2 (ja) 2019-08-21
CA3178098A1 (en) 2013-05-23
GB201220511D0 (en) 2012-12-26
EP2780022B1 (en) 2019-06-05
IL273107B (en) 2021-12-01
EP2780022B2 (en) 2022-09-07
IL287381B1 (en) 2023-12-01
IL232600B (en) 2020-03-31
HRP20191110T1 (hr) 2019-09-20
EP2780022A1 (en) 2014-09-24
IL308205B1 (en) 2025-06-01
GB2496969A (en) 2013-05-29
IL287381A (en) 2021-12-01
WO2013074681A1 (en) 2013-05-23
HK1202456A1 (en) 2015-10-02
CN113786417A (zh) 2021-12-14
CY1121819T1 (el) 2020-07-31
IL308205B2 (en) 2025-10-01
JP2021113193A (ja) 2021-08-05
PT2780022T (pt) 2019-07-16
JP7404441B2 (ja) 2023-12-25
AU2019201201B2 (en) 2021-04-08
JP7081016B2 (ja) 2022-06-06
IL232600A0 (en) 2014-06-30
AU2017225146B2 (en) 2019-01-17
IL287381B2 (en) 2024-04-01
AU2017225146A1 (en) 2017-10-05
FI2780022T4 (fi) 2023-07-06
TWI655286B (zh) 2019-04-01
SI2780022T1 (sl) 2019-09-30
AU2025201277A1 (en) 2025-03-13
IL308205A (en) 2024-01-01
JP2014533289A (ja) 2014-12-11
IL273107A (en) 2020-04-30
PL2780022T3 (pl) 2019-11-29
JP6506023B2 (ja) 2019-04-24
DK2780022T4 (da) 2024-09-09
TWI842079B (zh) 2024-05-11
TW201333200A (zh) 2013-08-16
US20130195806A1 (en) 2013-08-01
HUE044778T2 (hu) 2019-11-28
EP3563860A1 (en) 2019-11-06
AU2021204719A1 (en) 2021-08-05
TWI785403B (zh) 2022-12-01
DK2780022T3 (da) 2019-07-15
TW202120107A (zh) 2021-06-01
IL320536A (en) 2025-06-01
JP7716463B2 (ja) 2025-07-31
AU2017225146C1 (en) 2019-08-22
JP2025161815A (ja) 2025-10-24
JP2024037864A (ja) 2024-03-19
ES2734453T3 (es) 2019-12-10
TW202317157A (zh) 2023-05-01

Similar Documents

Publication Publication Date Title
JP7404441B2 (ja) ヒトｒｐｅ細胞医薬品およびその使用
HK40064545A (en) Pharmaceutical preparations of human rpe cells and uses thereof
HK40015631A (en) Pharmaceutical preparations of human rpe cells and uses thereof